Literature DB >> 22472569

MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells.

Lei Fan1, Qiang Wu, Xiaojuan Xing, Yulong Wei, Zengwu Shao.   

Abstract

MicroRNAs are important gene regulators that play a profound role in tumorigenesis. MicroRNA-145 (miR-145), an important member in the family of microRNAs, is under-expressed in several types of tumors and acts as a tumor suppressor. The role and probable pathways of miR-145 in osteosarcoma carcinogenesis are still unknown. In this study, we found that miR-145 was significantly under-expressed in osteosarcoma tissues, and the over-expression of miR-145 could inhibit invasion and angiopoiesis of osteosarcoma cells. Furthermore, the results showed that vascular endothelial growth factor (VEGF) expression was down-regulated in osteosarcoma cells after miR-145 transfection. On the basis of these results, we performed the luciferase assay and verified that miR-145 could down-regulate VEGF at the translational level by partially binding to VEGF 3' untranslated region (3'UTR). Therefore, it can be concluded that miR-145 can inhibit invasion and metastasis of osteosarcoma cells. One of the mechanisms is the down-regulation of VEGF expression by miR-145 by binding to the 3'UTR of VEGF mRNA specifically. These novel findings may have extensive implications for an effective gene therapy of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22472569     DOI: 10.1093/abbs/gms019

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  41 in total

1.  The effect of recombinant lentiviral vector encoding miR-145 on human esophageal cancer cells.

Authors:  Tian-Yun Wang; Qing-Qing Zhang; Xi Zhang; Qiu-Li Sun; Chun-Peng Zhao; Xiao-Yin Wang
Journal:  Tumour Biol       Date:  2015-07-09

Review 2.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

3.  Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma.

Authors:  Jie Yang; Tiantian Gao; Jie Tang; Haikang Cai; Lijun Lin; Shiping Fu
Journal:  Mol Cell Biochem       Date:  2013-06-26       Impact factor: 3.396

Review 4.  MiR-145: a potential biomarker of cancer migration and invasion.

Authors:  Wen-Xiu Xu; Zhen Liu; Fei Deng; Dan-Dan Wang; Xing-Wang Li; Tian Tian; Jian Zhang; Jin-Hai Tang
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

5.  Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts.

Authors:  Hao Hu; Yi Zhang; Xian-Hua Cai; Ji-Feng Huang; Lin Cai
Journal:  Oncol Lett       Date:  2012-08-16       Impact factor: 2.967

6.  MicroRNA-212 suppresses the proliferation and migration of osteosarcoma cells by targeting forkhead box protein A1.

Authors:  Jian Liu; Bohua Chen; Bin Yue; Junde Yang
Journal:  Exp Ther Med       Date:  2016-11-07       Impact factor: 2.447

Review 7.  MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects.

Authors:  Jinglei Miao; Song Wu; Zhi Peng; Mousumi Tania; Chaoyue Zhang
Journal:  Tumour Biol       Date:  2013-08

8.  microRNA-497 overexpression decreases proliferation, migration and invasion of human retinoblastoma cells via targeting vascular endothelial growth factor A.

Authors:  Jianjun Li; Yinghui Zhang; Xiuchao Wang; Ruibo Zhao
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

9.  Effect of microRNA-101 on proliferation and apoptosis of human osteosarcoma cells by targeting mTOR.

Authors:  Song Lin; Nan-Nan Shao; Lei Fan; Xiu-Cai Ma; Fei-Fei Pu; Zeng-Wu Shao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

10.  MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1.

Authors:  Enqi Li; Jinli Zhang; Tianxiang Yuan; Baotong Ma
Journal:  Tumour Biol       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.